Skip to main content

Satya Das Archives

Clinical score can guide PRRT therapy decisions for neuroendocrine tumors

Jan. 19, 2022—A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.

Read more


Shifts in neuroendocrine cancer clinical trial design

Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

Read more


Clinical trial tests ATR inhibitor in difficult-to-treat cancers

Sep. 23, 2021—  by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...

Read more


Das lands support for neuroendocrine tumor research

Mar. 5, 2020—Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more